바이오정보모아 (BioJungboMoa) — ADC · Antibody

8428프로그램 40FDA 승인

589오늘 방문

6,352누적 방문

7303갱신 대기 S–CData Tier S/A/B차세대 →Insight 1032HER2 breast 4683Antibody 2713CGT →Psoriasis →NSCLC 40FDA 승인

피드 Data Tier 차세대 Insight

Ociperlimab (Ociperlimab)

Advanced Hepatocellular Carcinoma · FRα

#FR#Antibody#Phase3#항체#면역항체+3

효능 ORR 100%임상시험 2상태 DISCONTINUED

ADCBiologicstaleSeagen Inc.Phase 1

SGN-75 (SGN-75)

Renal Cell Carcinoma · Carcinoma, Renal Cell

#CarcinomaRenalCell#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

임상시험 2상태 DISCONTINUED

AntibodystaleBristol Myers SquibbPhase 2

HF10 plus Ipilimumab (HF10 plus Ipilimumab)

Malignant Melanoma · Malignant Melanoma

#MalignantMelanoma#Antibody#Phase2#항체#면역항체+2

임상시험 2상태 ACTIVE

ADCBiologicstaleSeagen Inc.Phase 1

ASG-5ME (ASG-5ME)

Gastric Neoplasms; Pancreatic Neoplasms · Gastric Neoplasms

#GastricNeoplasms#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

임상시험 2상태 ACTIVE

AntibodystaleRochePhase 2

atezolizumab (Tecentriq, YL201 and atezolizumab)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#항체#면역항체+2

임상시험 2상태 RECRUITING

CGTBiologicstaleM.D. Anderson Cancer CenterPhase 2

TGFBR2 KO CAR27/IL-15 NK cells (TGFBR2 KO CAR27/IL-15 NK cells)

Gastric Cancer, Metastatic · Lymphoid

#Lymphoid#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 2상태 RECRUITING

CGTBiologicstaleHan weidongPhase 2

Decitabine-primed Tandem CAR19/20 engineered T cells (Decitabine-primed Tandem CAR19/20 engineered T cells)

Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 2상태 RECRUITING

ADCBiologicstaleBayerSN-38, which is predominant…Phase 1

BAY 3547922 (BAY 3547922)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3

임상시험 2상태 RECRUITING

ADCBiologicstaleEli Lilly and CompanyPhase 3

Sofetabart Mipitecan (Sofetabart Mipitecan)

Ovarian Neoplasms; Fallopian Tube Neoplasms · Ovarian Neoplasms

#OvarianNeoplasms#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

임상시험 2상태 RECRUITING

AntibodystaleAbbViePhase 1

Cofetuzumab Pelidotin (Cofetuzumab Pelidotin)

Cancer; Non-small Cell Lung Cancer (NSCLC) · Cancer

#Cancer#Antibody#Phase1#항체#면역항체+3

임상시험 2상태 DISCONTINUED

CGTBiologicstaleBeijing BiotechPhase 2

Dual-target CAR-NK cells (Dual-target CAR-NK cells)

Malignant Glioma; High-Grade Gliomas · Malignant Glioma

#MalignantGlioma#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 2상태 RECRUITING

CGTBiologicstaleGuangdong Xiangxue Precision Me…Phase 2

NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy） (NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）)

Soft Tissue Sarcoma · Bone Sarcoma

#BoneSarcoma#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 2상태 ACTIVE

ADCBiologicstaleQilu Pharmaceutical Co., Ltd.Phase 1

QLS5132 (QLS5132)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

임상시험 2상태 RECRUITING

CGTBiologicstaleMiltenyi Biomedicine GmbHPhase 1

T-cell Receptor-engineered T-cells (T-cell Receptor-engineered T-cells)

Prostate Carcinoma; Prostate Small Cell Neuroendocrine Carcinoma · Metastatic Malignant Solid Neoplasm

#MetastaticMalignantSolidNeoplasm#CGT#Phase1#세포유전치료#CAR-T+4

효능 ORR 32%임상시험 2상태 RECRUITING

CGTBiologicstaleTScan Therapeutics, Inc.Phase 2

E7 TCR (E7 TCR)

Papillomavirus Infections; Oropharyngeal Neoplasms · Cervical Intraepithelial Neoplasia

#CervicalIntraepithelialNeoplasia#CGT#Phase2#세포유전치료#CAR-T+4

효능 ORR 5%임상시험 2상태 DISCONTINUED

CGTBiologicstaleHenan Academy of Innovations in…Phase 1

Autologous NK cells (Autologous NK cells)

Malignant Solid Brain Tumors; Glioblastoma (GBM) · Malignant Solid Brain Tumors

#MalignantSolidBrainTumors#CGT#Phase1#세포유전치료#CAR-T+3

효능 ORR 0.667%임상시험 2상태 ACTIVE

CGTBiologicstaleImmune Design, a subsidiary of …Phase 1

Dendritic Cell-targeting Lentiviral Vector ID-LV305 (Dendritic Cell-targeting Lentiviral Vector ID-LV305)

HLA-A*0201 Positive Cells Present; NY-ESO-1 Positive Tumor Cells Present · HLA-A*0201 Positive Cells Present

#HLA-A0201PositiveCellsPresent#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 2상태 ACTIVE

CGTBiologicstaleGyala TherapeuticsPhase 1

CD84-CART (CD84-CART)

Relapsed/Refractory Acute Myeloid Leukemia(AML) · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 2상태 RECRUITING

ADCBiologicstaleGenentech, Inc.Phase 2

Pinatuzumab Vedotin (Pinatuzumab Vedotin)

Follicular Lymphoma; Diffuse Large B-Cell Lymphoma · Follicular Lymphoma

#FollicularLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 6.24%임상시험 2상태 ACTIVE

CGTBiologicstaleBiohaven Pharmaceuticals, Inc.Phase 2

CIML NK Cell Infusion (CIML NK Cell Infusion)

Squamous Cell Carcinoma of the Head and Neck; Recurrent Head and Neck Squamous Cell Carcinoma · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 2상태 ACTIVE

CGTBiologicstaleAnhui Kecheng intelligent healt…Phase 2

METR-NK cell（metabolic remodeling nature killer cells） (METR-NK cell（metabolic remodeling nature killer cells）)

Ovarian Cancer · Ovary Cancer

#OvaryCancer#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 2상태 RECRUITING

CGTBiologicstaleYake Biotechnology Ltd.Phase 2

BCMA CAR-T cells (BCMA CAR-T cells)

Multiple Myeloma; New Diagnosis Tumor · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 2상태 ACTIVE

CGTBiologicstaleSeigo NishidaPhase 1

Liver NK cell inoculation (Liver NK cell inoculation)

Liver Cirrhosis; Hepatocellular Carcinoma · Liver Cirrhosis

#LiverCirrhosis#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 2상태 ACTIVE

CGTBiologicstaleNational Heart, Lung, and Blood…Phase 2

ATLCAR.CD30 cells (ATLCAR.CD30 cells)

Lymphoma; Lymphoma, Non-Hodgkin · CD30

#CD30#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 2상태 RECRUITING

ADCBiologicstaleCSPC Megalith Biopharmaceutical…Phase 2

SYS6023 (SYS6023)

Advanced Breast Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 2상태 RECRUITING

54 / 142 페이지

← 이전 다음 →

전체 8,428개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 589 / 6,352

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

빠른 검색 · 이슈 태그

Ociperlimab (Ociperlimab)

SGN-75 (SGN-75)

HF10 plus Ipilimumab (HF10 plus Ipilimumab)

ASG-5ME (ASG-5ME)

atezolizumab (Tecentriq, YL201 and atezolizumab)

TGFBR2 KO CAR27/IL-15 NK cells (TGFBR2 KO CAR27/IL-15 NK cells)

Decitabine-primed Tandem CAR19/20 engineered T cells (Decitabine-primed Tandem CAR19/20 engineered T cells)

BAY 3547922 (BAY 3547922)

Sofetabart Mipitecan (Sofetabart Mipitecan)

Cofetuzumab Pelidotin (Cofetuzumab Pelidotin)

Dual-target CAR-NK cells (Dual-target CAR-NK cells)

NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy） (NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）)

QLS5132 (QLS5132)

T-cell Receptor-engineered T-cells (T-cell Receptor-engineered T-cells)

E7 TCR (E7 TCR)

Autologous NK cells (Autologous NK cells)

Dendritic Cell-targeting Lentiviral Vector ID-LV305 (Dendritic Cell-targeting Lentiviral Vector ID-LV305)

CD84-CART (CD84-CART)

Pinatuzumab Vedotin (Pinatuzumab Vedotin)

CIML NK Cell Infusion (CIML NK Cell Infusion)

METR-NK cell（metabolic remodeling nature killer cells） (METR-NK cell（metabolic remodeling nature killer cells）)

BCMA CAR-T cells (BCMA CAR-T cells)

Liver NK cell inoculation (Liver NK cell inoculation)

ATLCAR.CD30 cells (ATLCAR.CD30 cells)

SYS6023 (SYS6023)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

Ociperlimab (Ociperlimab)

SGN-75 (SGN-75)

HF10 plus Ipilimumab (HF10 plus Ipilimumab)

ASG-5ME (ASG-5ME)

atezolizumab (Tecentriq, YL201 and atezolizumab)

TGFBR2 KO CAR27/IL-15 NK cells (TGFBR2 KO CAR27/IL-15 NK cells)

Decitabine-primed Tandem CAR19/20 engineered T cells (Decitabine-primed Tandem CAR19/20 engineered T cells)

BAY 3547922 (BAY 3547922)

Sofetabart Mipitecan (Sofetabart Mipitecan)

Cofetuzumab Pelidotin (Cofetuzumab Pelidotin)

Dual-target CAR-NK cells (Dual-target CAR-NK cells)

NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy） (NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）)

QLS5132 (QLS5132)

T-cell Receptor-engineered T-cells (T-cell Receptor-engineered T-cells)

E7 TCR (E7 TCR)

Autologous NK cells (Autologous NK cells)

Dendritic Cell-targeting Lentiviral Vector ID-LV305 (Dendritic Cell-targeting Lentiviral Vector ID-LV305)

CD84-CART (CD84-CART)

Pinatuzumab Vedotin (Pinatuzumab Vedotin)

CIML NK Cell Infusion (CIML NK Cell Infusion)

METR-NK cell（metabolic remodeling nature killer cells） (METR-NK cell（metabolic remodeling nature killer cells）)

BCMA CAR-T cells (BCMA CAR-T cells)

Liver NK cell inoculation (Liver NK cell inoculation)

ATLCAR.CD30 cells (ATLCAR.CD30 cells)

SYS6023 (SYS6023)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

Ociperlimab (Ociperlimab)

SGN-75 (SGN-75)

HF10 plus Ipilimumab (HF10 plus Ipilimumab)

ASG-5ME (ASG-5ME)

atezolizumab (Tecentriq, YL201 and atezolizumab)

TGFBR2 KO CAR27/IL-15 NK cells (TGFBR2 KO CAR27/IL-15 NK cells)

Decitabine-primed Tandem CAR19/20 engineered T cells (Decitabine-primed Tandem CAR19/20 engineered T cells)

BAY 3547922 (BAY 3547922)

Sofetabart Mipitecan (Sofetabart Mipitecan)

Cofetuzumab Pelidotin (Cofetuzumab Pelidotin)

Dual-target CAR-NK cells (Dual-target CAR-NK cells)

NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy） (NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）)

QLS5132 (QLS5132)

T-cell Receptor-engineered T-cells (T-cell Receptor-engineered T-cells)

E7 TCR (E7 TCR)

Autologous NK cells (Autologous NK cells)

Dendritic Cell-targeting Lentiviral Vector ID-LV305 (Dendritic Cell-targeting Lentiviral Vector ID-LV305)

CD84-CART (CD84-CART)

Pinatuzumab Vedotin (Pinatuzumab Vedotin)